Direct oral anticoagulants in cardiology
Antithrombotic drug therapy is a main cornerstone - sometimes a fairly uneven cornerstone - of today's clinical practice. Patients treated with antithrombotic drugs appear sometimes unawaited at those of our colleagues, who are not necessarily experts of this narrow field. Furthermore, new and newer molecules of antiplatelet and anticoagulant medicines have come into practice, frequently in combination. This dramatic development has been important to patients; pharmacological - and recently nonpharmacological - antithrombotic treatment has paved the way to improve current modalities in cardiology. Combining elements of the "old four" (heparin, coumadin, aspirin, clopidogrel) have been the basis of any improvement for a long time. Nowadays, there has been an involvement of new drugs, direct oral anticoagulants into practice. It is time now to catch up in using new anticoagulants, regardless of our current speciality in medicine. Orv. Hetil., 2016, 157(38), 1507-1510.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:157 |
|---|---|
| Enthalten in: |
Orvosi hetilap - 157(2016), 38 vom: 12. Sept., Seite 1507-10 |
| Sprache: |
Ungarisch |
|---|
| Weiterer Titel: |
Direkt orális antikoagulánsok a kardiológiában |
|---|
| Beteiligte Personen: |
Kiss, Róbert Gábor [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 06.07.2017 Date Revised 02.12.2018 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1556/650.2016.30578 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM264446070 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM264446070 | ||
| 003 | DE-627 | ||
| 005 | 20231224210115.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2016 xx |||||o 00| ||hun c | ||
| 024 | 7 | |a 10.1556/650.2016.30578 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0881.xml |
| 035 | |a (DE-627)NLM264446070 | ||
| 035 | |a (NLM)27640616 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a hun | ||
| 100 | 1 | |a Kiss, Róbert Gábor |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Direct oral anticoagulants in cardiology |
| 246 | 3 | 3 | |a Direkt orális antikoagulánsok a kardiológiában |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.07.2017 | ||
| 500 | |a Date Revised 02.12.2018 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Antithrombotic drug therapy is a main cornerstone - sometimes a fairly uneven cornerstone - of today's clinical practice. Patients treated with antithrombotic drugs appear sometimes unawaited at those of our colleagues, who are not necessarily experts of this narrow field. Furthermore, new and newer molecules of antiplatelet and anticoagulant medicines have come into practice, frequently in combination. This dramatic development has been important to patients; pharmacological - and recently nonpharmacological - antithrombotic treatment has paved the way to improve current modalities in cardiology. Combining elements of the "old four" (heparin, coumadin, aspirin, clopidogrel) have been the basis of any improvement for a long time. Nowadays, there has been an involvement of new drugs, direct oral anticoagulants into practice. It is time now to catch up in using new anticoagulants, regardless of our current speciality in medicine. Orv. Hetil., 2016, 157(38), 1507-1510 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a antithrombotic therapy | |
| 650 | 4 | |a antithromboticus kezelés | |
| 650 | 4 | |a atrial fibrillation | |
| 650 | 4 | |a direct oral anticoagulants | |
| 650 | 4 | |a direkt orális antikoaguláns | |
| 650 | 4 | |a novel oral anticoagulants | |
| 650 | 4 | |a pitvarfibrilláció | |
| 650 | 4 | |a új orális antikoagulánsok | |
| 650 | 7 | |a Anticoagulants |2 NLM | |
| 650 | 7 | |a Fibrinolytic Agents |2 NLM | |
| 650 | 7 | |a Platelet Aggregation Inhibitors |2 NLM | |
| 650 | 7 | |a Warfarin |2 NLM | |
| 650 | 7 | |a 5Q7ZVV76EI |2 NLM | |
| 650 | 7 | |a Heparin |2 NLM | |
| 650 | 7 | |a 9005-49-6 |2 NLM | |
| 650 | 7 | |a Clopidogrel |2 NLM | |
| 650 | 7 | |a A74586SNO7 |2 NLM | |
| 650 | 7 | |a Ticlopidine |2 NLM | |
| 650 | 7 | |a OM90ZUW7M1 |2 NLM | |
| 650 | 7 | |a Aspirin |2 NLM | |
| 650 | 7 | |a R16CO5Y76E |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Orvosi hetilap |d 1949 |g 157(2016), 38 vom: 12. Sept., Seite 1507-10 |w (DE-627)NLM000021601 |x 1788-6120 |7 nnns |
| 773 | 1 | 8 | |g volume:157 |g year:2016 |g number:38 |g day:12 |g month:09 |g pages:1507-10 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1556/650.2016.30578 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 157 |j 2016 |e 38 |b 12 |c 09 |h 1507-10 | ||